Supplemental Table 8. Summary of reanalyzed associations and credibility assessment between antihypertensive treatment and cancer across observational studies

Intervention	Outcome	K	n/N	eOR (95% CI)	I^2	*P*	PI sign	LS sign	SSE	ESB	CE
ARBs	Incidence	39	381520/10985150	0.97 (0.90, 1.05)	95.4	0.465	N	N	N	Y	V
ACEIs	Incidence	72	270059/24270478	1.04 (1.00, 1.08)	83.3	0.069	N	Y	N	Y	V
$\beta-$ blockers	Incidence	66	148859/7451226	1.06 (1.01, 1.12)	83.6	0.012	N	Y	N	Y	IV
CCBs	Incidence	73	330620/11460069	1.07 (1.04, 1.10)	51.8	1.3×10^{-7}	N	Y	N	N	II
Diuretics	Incidence	85	323635/34372162	1.15 (1.10, 1.20)	88.5	8.1×10^{-11}	N	Y	Y	Y	II
ARBs	Cancer-specific mortality	4	NR/17842	0.81 (0.47, 1.38)	79.3	0.296	N	Y	NA	N	V
ACEIs	Cancer-specific mortality	4	1511/22345	0.86 (0.72, 1.04)	40.4	0.084	N	Y	NA	N	V
$\beta-$ blockers	Cancer-specific mortality	29	3202/307430	0.96 (0.90, 1.02)	62.6	0.228	N	Y	N	Y	V
CCBs	Cancer-specific mortality	5	NR/134357	1.04 (0.92, 1.18)	46.7	0.443	N	N	NA	Y	V
Diuretics	Cancer-specific mortality	3	NR/91955	1.19 (0.84, 1.68)	38.8	0.163	N	N	NA	N	V
$\beta-$ blockers	All-cause mortality	29	26046/272578	0.98 (0.93, 1.03)	64.6	0.381	N	N	Y	Y	V
ARBs	Overall survival	21	2979/561559	0.83 (0.74, 0.93)	81.4	0.0018	N	Y	N	Y	IV
ACEIs	Overall survival	20	23697/264595	0.94 (0.87, 1.03)	62.9	0.168	N	Y	N	Y	V
$\beta-$ blockers	Overall survival	70	8628/315317	0.92 (0.87, 0.97)	84.1	0.0027	N	N	Y	Y	IV
CCBs	Overall survival	15	65529/261296	1.06 (0.91, 1.22)	86.3	0.453	N	Y	N	N	V
Diuretics	Overall survival	4	4207/84116	1.18 (0.98, 1.42)	31.5	0.067	N	Y	NA	N	V
ACEIs	Disease-free survival	3	1924/5995	0.81 (0.09, 7.24)	85.2	0.717	N	N	NA	Y	V
$\beta-$ blockers	Disease-free survival	10	289/7927	0.75 (0.53, 1.06)	82.7	0.101	N	Y	Y	Y	V
ARBs	Cancer-specific survival	6	2212/6017	0.75 (0.52, 1.08)	76.7	0.100	N	Y	NA	N	V
ACEIs	Cancer-specific survival	3	1012/3735	1.18 (0.42, 3.30)	89.1	0.570	N	Y	NA	Y	V
$\beta-$ blockers	Cancer-specific survival	26	2826/93360	0.78 (0.69, 0.89)	82.2	0.00013	N	N	Y	N	III
ARBs	Progression-free survival	3	104/480	0.65 (0.42, 1.02)	0	0.054	N	N	NA	Y	V
ACEIs	Progression-free survival	3	NR/477	1.09 (0.34, 3.43)	77	0.788	N	N	NA	Y	V
$\beta-$ blockers	Progression-free survival	17	1176/11382	0.90 (0.81, 1.00)	40.9	0.051	N	N	N	N	V
CCBs	Progression-free survival	2	1056/2553	0.80 (0.10, 6.43)	35.8	0.406	N	N	NA	NA	V
$\beta-$ blockers	Recurrence-free survival	7	NR/37658	1.03 (0.79, 1.34)	62.1	0.770	N	N	NA	N	V

K, number of studies; n, number of cases; N, total number of participants; eOR, equivalent odds ratio; CI, confidence interval; *I*2, the proportion of the variance in observed effect is due to variance in true effects rather than sampling error; sign, significant; PI, prediction interval; LS sign, largest study with significant effect; SSE, small study effects; ESB, excess significance bias; CE, class of evidence; N, no; Y, yes; NR, not reported; NA, not assessable; ARBs, angiotensin receptor blockers; ACEIs, angiotensin converting enzyme inhibitors; CCBs, calcium channel blockers

Supplemental Table 9. Summary of reanalyzed associations and certainty assessment between antihypertensive treatment and cancer across randomized controlled trials

Intervention	Outcome	K	N	eOR (95% CI)	I^2	*P*	Imprecision	Inconsistency	RoB	Indirectness	PB	Upgrade	GRADE
ARBs	Incidence	29	163152	0.98 (0.94, 1.03)	4.6	0.450	V	V	V	↓	V	V	M
ACEIs	Incidence	32	162754	1.00 (0.96, 1.05)	0	0.842	V	V	V	↓	V	V	M
β − blockers	Incidence	13	90827	0.97 (0.91, 1.04)	0	0.410	V	V	V	↓	V	V	M
CCBs	Incidence	33	185777	1.06 (1.01, 1.12)	9.5	0.034	V	V	V	↓	V	V	M
Diuretics	Incidence	16	68601	1.00 (0.95, 1.06)	0	0.971	V	V	↓	↓	V	V	M
ARBs	Cancer-specific mortality	26	157089	1.02 (0.95, 1.11)	0	0.552	V	V	V	↓	V	V	M
ACEIs	Cancer-specific mortality	19	94917	0.95 (0.86, 1.06)	4.4	0.354	V	V	↓	↓	V	V	M
β − blockers	Cancer-specific mortality	13	76638	1.03 (0.93, 1.14)	0	0.571	V	V	↓↓	↓	V	V	L
CCBs	Cancer-specific mortality	16	87347	0.95 (0.87, 1.04)	0	0.291	V	V	↓	↓	V	V	M
Diuretics	Cancer-specific mortality	10	68276	1.01 (0.92, 1.13)	0	0.730	V	V	↓↓	↓	V	V	L
ARBs	All-cause mortality	5	68402	0.99 (0.89, 1.10)	61.9	0.765	V	V	V	↓	↓	V	M
β − blockers	All-cause mortality	12	1127	0.67 (0.38, 1.17)	0	0.157	V	V	↓↓	↓	V	V	L
β − blockers	Overall survival	3	8614	1.10 (0.81, 1.51)	33.5	0.307	V	V	↓↓	↓↓	↓	V	VL
CCBs	Overall survival	3	218	0.77 (0.63, 0.94)	0	0.030	V	V	↓↓	↓↓	↓	V	VL
β − blockers	Progression-free survival	4	6370	0.97 (0.72, 1.31)	46.3	0.772	V	V	↓↓	↓↓	↓	V	VL

GRADE, Grading of Recommendations, Assessment, Development, and Evaluations; K, number of studies; N, total number of participants; eOR, equivalent odds ratio; CI, confidence interval; I2, the proportion of the variance in observed effect is due to variance in true effects rather than sampling error; NR, not reported; NA, not assessable; ARBs, angiotensin receptor blockers; ACEIs, angiotensin converting enzyme inhibitors; CCBs, calcium channel blockers; RoB, risk of bias; PB, publication bias; VL, very low; L, low; M, moderate; H, high

Supplemental Table 10. Summary of reanalyzed associations, credibility, and certainty assessment between other antihypertensive treatments and cancer across observational studies and randomized controlled trials

Intervention	Outcome	K	n/N	eOR (95% CI)	I^2	*P*	PI sign	LS sign	SSE	ESB	CE
blockersα	Incidence	6	85181/343370	1.08 (0.91, 1.28)	93.2	0.303	N	Y	NA	N	V
PDE5Is	Incidence	11	23562/7249741	1.07 (1.00, 1.14)	89.2	0.040	N	Y	Y	N	IV
blockersα	Cancer-specific mortality	5	3704/140585	1.06 (0.80, 1.41)	93.4	0.600	N	Y	NA	Y	V
blockersα	All-cause mortality	5	8360/122411	1.02 (0.83, 1.25)	90	0.815	N	N	NA	Y	V

Intervention	Outcome	K	N	eOR (95% CI)	I^2	*P*	Imprecision	Inconsistency	RoB	Indirectness	PB	Upgrade	GRADE
Finerenone	Incidence	4	14902	0.97 (0.77, 1.23)	0	0.734	V	V	V	V	↓	V	M

K, number of studies; n, number of cases; N, total number of participants; eOR, equivalent odds ratio; CI, confidence interval; I2, the proportion of the variance in observed effect is due to variance in true effects rather than sampling error; sign, significant; PI, prediction interval; LS sign, largest study with significant effect; SSE, small study effects; ESB, excess significance bias; CE, class of evidence; N, no; Y, yes; NA, not assessable; PDE5Is, phosphodiesterase 5 inhibitors; GRADE, Grading of Recommendations, Assessment, Development, and Evaluations; RoB, risk of bias; PB, publication bias; M, moderate

Supplemental Table 11. Summary characteristics of included original research articles across meta-analyses of observational studies

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Azoulay et al, 2012	CC	Overall	6.4	ARBs	Incidence
Bhaskaran et al, 2012	Cohort	Overall	4.6	ARBs	Incidence
Cardwell et al, 2014	NCC	Colorectal	NR	ARBs	Incidence
Chang et al, 2011	CC	Overall	7.4	ARBs	Incidence
Chang et al, 2016	CC	Breast	NR	ARBs	Incidence
Chin et al, 2011	Cohort	Pancreatic	5	ARBs	Incidence
Chuang et al, 2017	CC	Overall	NR	ARBs	Incidence
Daniels et al, 2020	CC	Melanoma	NR	ARBs	Incidence
Deshpande et al, 2013	CC	Colorectal	NR	ARBs	Incidence
Dierssen-Sotos et al, 2017	CC	Colorectal	NR	ARBs	Incidence
Drucker et al, 2021	Cohort	Melanoma	NR	ARBs	Incidence
FaCCiorusso et al, 2015	Cohort	HCC	88 m	ARBs	Incidence
Fryzek et al, 2006	Cohort	Breast	5	ARBs	Incidence
Fryzek JP et al, 2005	Cohort	RCC	NR	ARBs	Incidence
Fujimoto et al, 2017	Cohort	Melanoma	NR	ARBs	Incidence
Gomez-Acebo et al, 2016	CC	Breast	NR	ARBs	Incidence
Hallas et al, 2012	CC	Overall	7.8	ARBs	Incidence
Huang et al, 2011	Cohort	Overall	5.7	ARBs	Incidence
Jung et al, 2021	Cohort	Lung	NR	ARBs	Incidence
Kemppainen, 2011	CC	Overall	< 1 to > 6	ARBs	Incidence
Kirkegård et al, 2019	Cohort	Pancreatic	5	ARBs	Incidence
Koomen et al, 2009	CC	Melanoma	≥ 3	ARBs	Incidence
Kumar et al, 2021	Cohort	Lung	NR	ARBs	Incidence
Leung et al, 2015	CC	Breast	NR	ARBs	Incidence
Li et al, 2013	CC	Breast	< 5 to > 10	ARBs	Incidence
Lin et al, 2020	Cohort	Lung	NR	ARBs	Incidence
Mackenzie et al, 2016	Cohort	Bladder	NR	ARBs	Incidence
Mandilaras et al, 2017	Cohort	Pancreatic	5.2	ARBs	Incidence
Moon et al, 2020	Cohort	Lung	7.8	ARBs	Incidence
Nardone et al, 2017	Cohort	Skin	4	ARBs	Incidence
Pasternak et al, 2011	Cohort	Overall	2.9	ARBs	Incidence
Pottegard et al, 2018	CC	Melanoma	NR	ARBs	Incidence
Rao et al, 2013	Cohort	Overall	4.5-8	ARBs	Incidence
Schmidt et al, 2015	CC	Skin	Maximize: 19	ARBs	Incidence
Su et al, 2018	Cohort	SCC	NR	ARBs	Incidence
Sugiura et al, 2012	Cohort	Overall	NR	ARBs	Incidence
Tascilar et al, 2016	Cohort	Lung	NR	ARBs	Incidence
Wang et al, 2013	Cohort	Overall	4.8	ARBs	Incidence
Wilson et al, 2016	Cohort	Breast	NR	ARBs	Incidence
Anderson et al, 2021	Cohort	Lung	7.1	ACEIs	Incidence

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Assimes et al, 2008	CC	Overall	3.6	ACEIs	Incidence
Azoulay et al, 2012	NCC	Overall	6.4	ACEIs	Incidence
Bhaskaran et al, 2012	Cohort	Lung	4.6	ACEIs	Incidence
Boudreau et al, 2008	CC	Colorectal	NR	ACEIs	Incidence
Cardwell et al, 2014	NCC	Colorectal	NR	ACEIs	Incidence
Chae et al, 2011	Cohort	Breast	4.6	ACEIs	Incidence
Chang et al, 2011	CC	Overall	NR	ACEIs	Incidence
Chen et al, 2015	CC	Breast	NR	ACEIs	Incidence
Chiang et al, 2014	Cohort	Lung	2.3	ACEIs	Incidence
Chin et al, 2011	Cohort	Pancreatic	5	ACEIs	Incidence
Chuang et al, 2017	CC	Overall	NR	ACEIs	Incidence
Colt et al, 2017	CC	RCC	NR	ACEIs	Incidence
Daniels et al, 2020	CC	Melanoma	NR	ACEIs	Incidence
Deshpande et al, 2013	CC	Colorectal	NR	ACEIs	Incidence
Devore et al, 2015	Cohort	Breast	10.6-13.2	ACEIs	Incidence
Dierssen-Sotos et al, 2017	CC	Colorectal	NR	ACEIs	Incidence
Drucker et al, 2021	Cohort	Melanoma	NR	ACEIs	Incidence
FaCCiorusso et al, 2015	Cohort	HCC	88 m	ACEIs	Incidence
Fitzpatrick et al, 1997	Cohort	Breast	4.6	ACEIs	Incidence
Fitzpatrick et al, 2001	Cohort	Prostate	5.2	ACEIs	Incidence
Friis et al, 2001	Cohort	Overall	3.7	ACEIs	Incidence
Fryzek et al, 2006	Cohort	Breast	NR	ACEIs	Incidence
Fryzek et al, 2005	Cohort	RCC	NR	ACEIs	Incidence
Gomez-Acebo et al, 2016	CC	Breast	NR	ACEIs	Incidence
Gonzalez-Perez et al, 2004	NCC	Breast	NR	ACEIs	Incidence
Hallas et al, 2012	CC	Overall	7.8	ACEIs	Incidence
Helgeson et al, 2021	Cohort	Lung	9	ACEIs	Incidence
Hicks et al, 2018	Cohort	Lung	6.4	ACEIs	Incidence
Jick et al, 1997	NCC	Lung	NR	ACEIs	Incidence
Jung et al, 2021	Cohort	Lung	6	ACEIs	Incidence
Kaae et al, 2010	Cohort	Overall	NA (1–10)	ACEIs	Incidence
Kedika et al, 2011	Cohort	Colorectal	NR	ACEIs	Incidence
Kemppainen et al, 2011	CC	Prostate	NR	ACEIs	Incidence
Kirkegård et al, 2019	Cohort	Pancreatic	5	ACEIs	Incidence
Koomen et al, 2009	CC	Melanoma	≥ 3	ACEIs	Incidence
Kristensen et al, 2021	CC	Lung	5.6	ACEIs	Incidence
Kumar et al, 2021	Cohort	Lung	7.1	ACEIs	Incidence
Largent et al, 2010	Cohort	Breast	6.3	ACEIs	Incidence
Lee et al, 2012	CC	Breast	NR	ACEIs	Incidence
Leung et al, 2015	CC	Breast	NR	ACEIs	Incidence
Lever et al, 1998	Cohort	Any	6.6	ACEIs	Incidence

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Li et al, 2013	CC	Breast	NR	ACEIs	Incidence
Li et al, 2003	CC	Breast	NR	ACEIs	Incidence
Lin et al, 2020	Cohort	Lung	6.2	ACEIs	Incidence
Mackenzie et al, 2016	Cohort	Bladder	NR	ACEIs	Incidence
Mandilaras et al, 2017	Cohort	Pancreatic	5.2	ACEIs	Incidence
Mansouri et al, 2013	NCC	Colorectal	NR	ACEIs	Incidence
McLaughlin et al, 1995	CC	RCC	NR	ACEIs	Incidence
Meier et al, 2000	CC	Breast	NR	ACEIs	Incidence
Mellemgaard et al, 1994	CC	RCC	NR	ACEIs	Incidence
Meng et al, 2021	CC	Lung	1.7	ACEIs	Incidence
Nardone et al, 2017	Cohort	Skin	4	ACEIs	Incidence
Pahor et al, 1996	Cohort	Any	NA (≤ 5)	ACEIs	Incidence
Pasternak et al, 2011	Cohort	Lung	2.5	ACEIs	Incidence
Perez et al, 2004	NCC	Breast	3	ACEIs	Incidence
Perron et al, 2004	CC	Prostate	NR	ACEIs	Incidence
Pogoda et al, 2005	CC	AML	NR	ACEIs	Incidence
Pottegard et al, 2018	CC	Melanoma	NR	ACEIs	Incidence
Rodriguez et al, 2009	Cohort	Prostate	6.3	ACEIs	Incidence
Ronquist et al, 2004	NCC	Prostate	NR	ACEIs	Incidence
Rosenberg et al, 1998	CC	Overall	NR	ACEIs	Incidence
Saltzman et al, 2013	Cohort	Breast	NR	ACEIs	Incidence
Schmidt et al, 2015	CC	Skin	Maximum, 19	ACEIs	Incidence
Shapiro et al, 1999	CC	RCC	NR	ACEIs	Incidence
Sjoberg et al, 2007	NCC	Esophageal or Gastric	NR	ACEIs	Incidence
Su et al, 2018	Cohort	SCC	NR	ACEIs	Incidence
Tseng et al, 2011	Cohort	Bladder	NR	ACEIs	Incidence
van der Knaap et al, 2008	Cohort	Lung	9.6	ACEIs	Incidence
Vezina et al, 1998	CC	Prostate	NR	ACEIs	Incidence
Wang et al, 2018	Cohort	Pancreatic	13.8	ACEIs	Incidence
Wilson et al, 2016	Cohort	Breast	NR	ACEIs	Incidence
Assimes et al, 2008	NCC	Overall	NR	β-blockers	Incidence
Boudreau et al, 2014	Cohort	Breast	75.6 m	β-blockers	Incidence
Chang et al, 2016	NCC	Breast	9.9	β-blockers	Incidence
Chang et al, 2015	Cohort	Overall	12	β-blockers	Incidence
Chen et al, 2015	CC	Breast	NA	β-blockers	Incidence
Chen et al, 2022	Cohort	HCC	NR	β-blockers	Incidence
Cholongitas et al, 2006	Cohort	HCC	NR	β-blockers	Incidence
Christian et al, 2008	Cohort	Skin	3.4	β-blockers	Incidence
Colt et al, 2017	CC	RCC	NR	β-blockers	Incidence
Davis and Mirick. 2007	CC	Breast	120 m	β-blockers	Incidence
Deshpande et al, 2013	CC	Colorectal	NR	β-blockers	Incidence

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Devore et al, 2015	Cohort	Breast	NR	β-blockers	Incidence
Drucker et al, 2021	Cohort	Melanoma	NR	β-blockers	Incidence
Fitzpatrick et al, 2001	Cohort	Prostate	5.6	β-blockers	Incidence
Friedman et al, 2011	CC	Colon	>2 years	β-blockers	Incidence
Fryzek et al, 2006	Cohort	Breast	5.7	β-blockers	Incidence
Fryzek et al, 2005	Cohort	RCC	NR	β-blockers	Incidence
Ghiasvand et al, 2022	CC	Melanoma	NR	β-blockers	Incidence
Giannelli et al, 2020	Cohort	HCC	NR	β-blockers	Incidence
Gimenez et al, 2018	Cohort	HCC	NR	β-blockers	Incidence
Gomez-Acebo et al, 2016	CC	Breast	NR	β-blockers	Incidence
Gonzalez-Perez et al, 2004	NCC	Breast	NR	β-blockers	Incidence
Gonzalez-Suarez et al, 2006	Cohort	HCC	NR	β-blockers	Incidence
Gottschau et al, 2022	Cohort	Breast	57.6 m	β-blockers	Incidence
Hole et al, 1993	Cohort	Overall	NR	β-blockers	Incidence
Jansen et al, 2012	CC	Colorectal	>2 years	β-blockers	Incidence
Kaae et al, 2010	Cohort	Skin	NR	β-blockers	Incidence
Kang et al, 2021	Cohort	HCC	NR	β-blockers	Incidence
Kemppainen et al, 2011	CC	Prostate	NR	β-blockers	Incidence
Kim et al, 2012	Cohort	HCC	NR	β-blockers	Incidence
Lee et al, 2020	Cohort	HCC	NR	β-blockers	Incidence
Leithead et al, 2014	Cohort	HCC	NR	β-blockers	Incidence
Leung et al, 2015	CC	Breast	NR	β-blockers	Incidence
Li et al, 2003	CC	Breast	NR	β-blockers	Incidence
Li et al, 2013	CC	Breast	NR	β-blockers	Incidence
Lin et al, 2015	Cohort	Overall	4.9 - 5.1	β-blockers	Incidence
Makar et al, 2014	NCC	Colorectal	>1 year	β-blockers	Incidence
MCCredi et al, 1992	CC	RCC	NR	β-blockers	Incidence
McDowell et al, 2021	Cohort	HCC	NR	β-blockers	Incidence
McLaughlin et al, 1995	CC	RCC	NR	β-blockers	Incidence
Meier et al, 2000	CC	Breast	63.6	β-blockers	Incidence
Mellemgaard et al, 1994	CC	RCC	NR	β-blockers	Incidence
Moscarelli et al, 2010	Cohort	Skin	4.9	β-blockers	Incidence
Ngwa et al, 2016	Cohort	HCC	NR	β-blockers	Incidence
Nkontchou et al, 2012	Cohort	HCC	NR	β-blockers	Incidence
Numbere et al, 2017	CC	Overall	NR	β-blockers	Incidence
Perron et al, 2004	CC	Prostate	NR	β-blockers	Incidence
Rodriguez et al, 2009	Cohort	Prostate	8	β-blockers	Incidence
Ronquist et al, 2004	NCC	Prostate	NR	β-blockers	Incidence
Rosenberg et al, 1998	CC	Breast	NR	β-blockers	Incidence
Saltzman et al, 2013	Cohort	Breast	60 m	β-blockers	Incidence
Scheiner et al, 2017	Cohort	HCC	NR	β-blockers	Incidence

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Schmidt et al, 2015	CC	Skin	Maximum, 19	$\beta-$ blockers	Incidence
Schouten et al, 2005	Cohort	RCC	NR	β-blockers	Incidence
Shapiro et al, 1999	CC	RCC	NR	β-blockers	Incidence
Sinha et al, 2017	Cohort	HCC	NR	β-blockers	Incidence
Snoga et al, 2020	Cohort	HCC	NR	β-blockers	Incidence
Su et al, 2018	Cohort	SCC	NR	β-blockers	Incidence
Vezina et al, 1998	CC	Prostate	NR	β-blockers	Incidence
Wallen et al, 2017	Cohort	HCC	NR	β-blockers	Incidence
Weinman et al, 1994	CC	RCC	NR	β-blockers	Incidence
Westerdahl et al, 1996	CC	Melanoma	NR	β-blockers	Incidence
Wijarnpreecha et al, 2021	Cohort	HCC	NR	β-blockers	Incidence
Wilson et al, 2016	Cohort	Breast	5.3	β-blockers	Incidence
Yeh et al, 2019	Cohort	HCC	NR	β-blockers	Incidence
Zheng et al, 2021	Cohort	Breast	24 - 46.5 m	β-blockers	Incidence
Assimes et al, 2008	NCC	Overall	5.0-8.0	CCBs	Incidence
Azoulay et al, 2016	Cohort	Breast	5.7	CCBs	Incidence
Azoulay et al, 2012	NCC	Overall	5.5-6.4	CCBs	Incidence
Beiderbeck Noll et al, 2003	Cohort	Overall	4.7-5.2	CCBs	Incidence
Bergman et al, 2014	CC	Breast	5	CCBs	Incidence
Boudreau et al, 2008	CC	Colorectal	NR	CCBs	Incidence
Brasky et al, 2017	CC	Breast	NR	CCBs	Incidence
Braun et al, 1998	Cohort	Overall	2.8	CCBs	Incidence
Busby et al, 2018	CC	Breast	NR	CCBs	Incidence
Chang et al, 2016	NCC	Breast	11	CCBs	Incidence
Chen et al, 2015	CC	Breast	NR	CCBs	Incidence
Cheung et al, 2020	Cohort	Colorectal	NR	CCBs	Incidence
Christian et al, 2008	Cohort	Overall	3.4	CCBs	Incidence
Chuang et al, 2017	CC	Overall	7	CCBs	Incidence
Colt JS et al, 2017	CC	RCC	NR	CCBs	Incidence
Daniels et al, 2020	CC	Melanoma	NR	CCBs	Incidence
Davis and Mirick. 2007	CC	Breast	5.0-8.0	CCBs	Incidence
Debes et al, 2004	Cohort	Prostate	10	CCBs	Incidence
Deshpande et al, 2013	CC	Colorectal	NR	CCBs	Incidence
Devore et al, 2015	Cohort	Breast	NR	CCBs	Incidence
Drucker et al, 2021	Cohort	Melanoma	NR	CCBs	Incidence
Fitzpatrick et al, 1997	Cohort	Breast	5	CCBs	Incidence
Fitzpatrick et al, 2001	Cohort	Prostate	5.6	CCBs	Incidence
Fortuny et al, 2007	CC	Overall	NR	CCBs	Incidence
Fryzek et al, 2006	Cohort	Breast	13	CCBs	Incidence
Fryzek et al, 2005	Cohort	RCC	NR	CCBs	Incidence
Geybels et al, 2017	CC	Prostate	NR	CCBs	Incidence

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Ghiasvand et al, 2022	CC	Melanoma	NR	CCBs	Incidence
Gomez-Acebo et al, 2016	CC	Breast	NR	CCBs	Incidence
Gonzalez-Perez et al, 2004	NCC	Breast	5	CCBs	Incidence
Grimaldi et al, 2016	Cohort	Overall	at least 2	CCBs	Incidence
Guercio et al, 2019	CC	Bladder	NR	CCBs	Incidence
Hole et al, 1998	Cohort	Overall	5 - 6.6	CCBs	Incidence
Holmes et al, 2013	Cohort	Overall	1.0-5.0	CCBs	Incidence
Jick et al, 1997	NCC	Overall	5	CCBs	Incidence
Kaae et al, 2010	Cohort	Overall	NR	CCBs	Incidence
Kao et al, 2018	Cohort	Prostate	5	CCBs	Incidence
Kemppainen et al, 2011	CC	Prostate	NR	CCBs	Incidence
Lamiae et al, 2016	Cohort	Prostate	At least 2	CCBs	Incidence
Largent et al, 2010	Cohort	Breast	10	CCBs	Incidence
Leung et al, 2015	CC	Breast	13	CCBs	Incidence
Li et al, 2003	CC	Breast	2	CCBs	Incidence
Li et al, 2013	CC	Breast	9	CCBs	Incidence
Makar et al, 2014	NCC	Colorectal	>1 year	CCBs	Incidence
McLaughlin et al, 1995	CC	RCC		CCBs	Incidence
Meier et al, 2000	CC	Breast	5.3	CCBs	Incidence
Mellemgaard et al, 1994	CC	RCC	NR	CCBs	Incidence
Michels et al, 1998	Cohort	Overall	6	CCBs	Incidence
Moscarelli et al, 2010	Cohort	Overall	4.9	CCBs	Incidence
Numbere et al, (2015)	CC	Overall	NR	CCBs	Incidence
Olsen et al, 1997	Cohort	Overall	1.8 - 3	CCBs	Incidence
Pahor et al, 1996	Cohort	Overall	3.7	CCBs	Incidence
Perron et al, 2004	CC	Prostate	8	CCBs	Incidence
Pottegard et al, 2018	CC	Melanoma	NR	CCBs	Incidence
Raebel et al, 2017	Cohort	Breast	NR	CCBs	Incidence
Ranka et al, 2006	CC	Esophageal	NR	CCBs	Incidence
Rodriguez et al, 2009	Cohort	Prostate	8	CCBs	Incidence
Ronquist et al, 2004	NCC	Prostate	2-4.5	CCBs	Incidence
Rosenberg et al, 1998	CC	Overall	3.8	CCBs	Incidence
Rotshild et al, 2019	NCC	Prostate	5.3	CCBs	Incidence
Sajadieh et al, 1999	Cohort	Overall	1.2	CCBs	Incidence
Saltzman et al, 2013	Cohort	Breast	12	CCBs	Incidence
Santala et al, 2018	Cohort	Prostate	10.3	CCBs	Incidence
Schmidt et al, 2015	CC	Overall	Maximum, 19	CCBs	Incidence
Shapiro et al, 1999	CC	RCC	NR	CCBs	Incidence
Siltari et al, 2018	Cohort	Prostate	16	CCBs	Incidence
Soldera et al, 2015	Cohort	Breast	NR	CCBs	Incidence
Sorensen et al, 2000	Cohort	Overall	3.2	CCBs	Incidence

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Su et al, 2018	Cohort	SCC	NR	CCBs	Incidence
Tseng et al, 2011	Cohort	Bladder	NR	CCBs	Incidence
Vaughan et al, 1998	CC	Overall	NR	CCBs	Incidence
Vezina et al, 1998	CC	Prostate	2	CCBs	Incidence
Wilson et al, 2016	Cohort	Breast	NR	CCBs	Incidence
MCCredi et al, 1992	CC	RCC	NR	Diuretics	Incidence
McDonald et al, 2014	Cohort	BCC	8.7	Diuretics	Incidence
McLaughlin et al, 1995	CC	RCC	NR	Diuretics	Incidence
Mellemgaard et al, 1992	Cohort	RCC	NR	Diuretics	Incidence
Mellemgaard et al, 1994	CC	RCC	NR	Diuretics	Incidence
Morales et al, 2020	NCC	Overall	NR	Diuretics	Incidence
Nardone et al, 2017	Cohort	Overall	4	Diuretics	Incidence
Park et al, 2020	Cohort	Overall	NR	Diuretics	Incidence
Pedersen et al, 2018	NCC	Overall	NR	Diuretics	Incidence
Pedersen et al, 2019	CC	MCC	NR	Diuretics	Incidence
Pottegård et al, 2018	NCC	Melanoma	NR	Diuretics	Incidence
Pottegård et al, 2019	NCC	Overall	NR	Diuretics	Incidence
Pottegård et al, 2017	NCC	Lip	NR	Diuretics	Incidence
Prineas et al, 1997	Cohort	RCC	NR	Diuretics	Incidence
Robinson et al, 2013	NCC	SCC	NR	Diuretics	Incidence
Ronquist et al, 2004	NCC	Prostate	NR	Diuretics	Incidence
Rouette et al, 2021	Cohort	Overall	NR	Diuretics	Incidence
Ruiter et al, 2010	Cohort	BCC	Maximum, 20	Diuretics	Incidence
Sabatier et al, 2019	CC	Breast	NR	Diuretics	Incidence
Saltzman et al, 2013	Cohort	Breast	NR	Diuretics	Incidence
Schmidt et al, 2015	NCC	Overall	Maximum, 19	Diuretics	Incidence
Schneider et al, 2021	Cohort	Overall	NR	Diuretics	Incidence
Schouten et al, 2005	Cohort	RCC	NR	Diuretics	Incidence
Setiawan et al, 2007	Cohort	RCC	NR	Diuretics	Incidence
Shapiro et al, 1999	CC	RCC	NR	Diuretics	Incidence
Su et al, 2018	Cohort	SCC	NR	Diuretics	Incidence
Tenenbaum et al, 2001	Cohort	Colon	4–7	Diuretics	Incidence
Tiba et al, 2022	CC	NMSC	NR	Diuretics	Incidence
Vezina et al, 1998	CC	Prostate	NR	Diuretics	Incidence
Weinman et al, 1994	CC	RCC	NR	Diuretics	Incidence
Westerdahl et al, 1996	CC	Melanoma	nr	Diuretics	Incidence
Wilson et al, 2016	Cohort	Breast	5.3	Diuretics	Incidence
Yeon et al, 2020	CC	NMSC	NR	Diuretics	Incidence
Yu et al, 1986	CC	RCC	NR	Diuretics	Incidence
Yuan et al, 1998	CC	RCC	NR	Diuretics	Incidence
Murtola et al, 2007	CC	Prostate	NR	α blockers	Incidence

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Murtola et al, 2009	Cohort	Prostate	NR	α blockers	Incidence
Robinson et al, 2013	CC	Prostate	NR	α blockers	Incidence
Preston et al, 2014	Cohort	Prostate	NR	α blockers	Incidence
Boehm et al, 2015	CC	Prostate	NR	α blockers	Incidence
Rompay et al, 2019	Cohort	Prostate	NR	α blockers	Incidence
Li et al, 2014	Cohort	Overall	7.9	PDE5Is	Incidence
Loeb et al, 2015	NCC	Overall	NR	PDE5Is	Incidence
Matthews et al, 2016	Cohort	Overall	15-23.8	PDE5Is	Incidence
Pottegård et al, 2016	CC	Melanoma	NR	PDE5Is	Incidence
Lian et al, 2016	Cohort	Overall	4.8	PDE5Is	Incidence
Loeb et al, 2016	CC	Overall	NR	PDE5Is	Incidence
Shkolyar et al, 2018	Cohort	Overall	4.2	PDE5Is	Incidence
Christie et al, 2019	Cohort	Overall	8.7	PDE5Is	Incidence
Huang et al, 2019	Cohort	Colorectal	4.0-10	PDE5Is	Incidence
Soriano et al, 2019	CC	Colorectal	11	PDE5Is	Incidence
Sutton et al, 2020	Cohort	Colorectal	15	PDE5Is	Incidence
Chin et al, 2011	Cohort	Pancreatic	5	ARBs	CSM
Cerullo et al, 2017	Cohort	Pancreatic	2.5	ARBs	CSM
Støer et al, 2021	Cohort	Pancreatic	0.5	ARBs	CSM
Keith et al, 2022	Cohort	Pancreatic	0.5	ARBs	CSM
Chin et al, 2011	Cohort	Pancreatic	5	ACEIs	CSM
Cardwell et al, 2014	NCC	Colorectal	NR	ACEIs	CSM
Støer et al, 2021	Cohort	Pancreatic	0.5	ACEIs	CSM
Keith et al, 2022	Cohort	Pancreatic	0.5	ACEIs	CSM
Hole et al, 1993	Cohort	Overall	NR	β-blockers	CSM
Powe et al, 2010	Cohort	Breast	124 m	β-blockers	CSM
Barron et al, 2011	Cohort	Breast	2.7 - 3.6	β-blockers	CSM
Ganz et al, 2011	Cohort	Breast	8.2	β-blockers	CSM
Lemeshow et al, 2011	Cohort	Melanoma	4.9	β-blockers	CSM
Botteri et al, 2013	Cohort	Breast	6	β-blockers	CSM
Cardwell et al, 2013	NCC	Breast	3.9	β-blockers	CSM
Chae et al, 2013	Cohort	Breast	4.6	β-blockers	CSM
Grytli et al, 2013	Cohort	Prostate	70 m	β-blockers	CSM
Hicks et al, 2013	NCC	Colorectal	6.2	β-blockers	CSM
Holmes et al, 2013	Cohort	Breast	10.5	β-blockers	CSM
Assayag et al, 2014	Cohort	Prostate	3.8	β-blockers	CSM
Cardwell et al, 2014	NCC	Prostate	72 m	β-blockers	CSM
Grytli et al, 2014	Cohort	Prostate	39 m	β-blockers	CSM
Jansen et al, 2014	Cohort	Colorectal	5	β-blockers	CSM
MCCourt et al, 2014	NCC	Melanoma	NR	β-blockers	CSM
Cardwell et al, 2016	Cohort	Breast	4–6	β-blockers	CSM

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Chen et al, 2017	Cohort	Breast	3	β-blockers	CSM
Musselman et al, 2018	Cohort	Breast	4.8	β-blockers	CSM
Cui et al, 2019	Cohort	Breast	6.3	β-blockers	CSM
Santala et al, 2019	Cohort	Prostate	125 m	β-blockers	CSM
Santala et al, 2020	Cohort	Breast	6.2	β-blockers	CSM
Siltari et al, 2020	Cohort	Prostate	97 m	β-blockers	CSM
Gillis et al, 2021	Cohort	Breast	5.5	β-blockers	CSM
Lorona et al, 2021	Cohort	Breast	NR	β-blockers	CSM
Posielski et al, 2021	Cohort	Prostate	134 m	β-blockers	CSM
Lofling et al, 2022	Cohort	Breast	5.1	β-blockers	CSM
Scott et al, 2022	Cohort	Breast	4.5	β-blockers	CSM
Chang et al, 2023	Cohort	Breast	NR	β-blockers	CSM
Holmes et al, 2013	Cohort	Breast	NR	CCBs	CSM
Sorensen et al, 2013	Cohort	Breast	NR	CCBs	CSM
Chen et al, 2017	Cohort	Breast	NR	CCBs	CSM
Busby et al, 2018	Cohort	Breast	NR	CCBs	CSM
Santala et al, 2020	Cohort	Breast	NR	CCBs	CSM
Holmes et al, 2013	Cohort	Breast	NR	Diuretics	CSM
Chen et al, 2017	Cohort	Breast	NR	Diuretics	CSM
Santala et al, 2020	Cohort	Breast	NR	Diuretics	CSM
Kjellman et al, 2013	Cohort	Prostate	NR	α blockers	CSM
Murtola et al, 2016	Cohort	Prostate	NR	α blockers	CSM
Kumar et al, 2019	Cohort	Prostate	NR	α blockers	CSM
Sarkar et al, 2019	Cohort	Prostate	NR	α blockers	CSM
Rompay et al, 2019	Cohort	Prostate	NR	α blockers	CSM
Ganz et al, 2011	Cohort	Breast	8.2	β-blockers	ACM
Melhem Bertrandt et al, 2011	Cohort	Breast	5.1	β-blockers	ACM
Shah et al, 2011	Cohort	Breast	4.8	β-blockers	ACM
Cardwell et al, 2016	Cohort	Breast	4-6	β-blockers	ACM
Lemeshow et al, 2011	Cohort	Melanoma	4.9	β-blockers	ACM
Diaz et al, 2012	Cohort	Ovarian	27 m	β-blockers	ACM
Yusuf et al, 2012	Cohort	Overall	1.25	β-blockers	ACM
Botteri et al, 2013	Cohort	Breast	Users: 72 m, Nonusers: 68 m	β-blockers	ACM
Grytli et al, 2013	Cohort	Prostate	122 m	β-blockers	ACM
Holmes et al, 2013	Cohort	Overall	4.2 - 10.5	β-blockers	ACM
Johannesdottir et al, 2013	Cohort	Ovarian	2.5	β-blockers	ACM
Hicks et al, 2013	NCC	Colorectal	6.2	β-blockers	ACM
Aydiner et al, 2013	Cohort	Lung	17.8 m	β-blockers	ACM
Wang et al, 2013	Cohort	Lung	44 m	β-blockers	ACM
Livingstone et al, 2013	Cohort	Melanoma	39 m	β-blockers	ACM
Chae et al, 2013	Cohort	Breast	4.6	β-blockers	ACM

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Grytli et al, 2014	Cohort	Prostate	39 m	β-blockers	ACM
Cardwell et al, 2014	NCC	Prostate	72 m	β-blockers	ACM
Assayag et al, 2014	Cohort	Prostate	3.8	β-blockers	ACM
Jansen et al, 2014	Cohort	Colorectal	5	β-blockers	ACM
Cata et al, 2014	Cohort	Lung	5	β-blockers	ACM
De Giorgi et al, 2014	Cohort	Melanoma	4.2	β-blockers	ACM
MCCourt et al, 2014	NCC	Melanoma	NR	β-blockers	ACM
Chae et al, 2014	Cohort	AML	NR	β-blockers	ACM
Musselman et al, 2014	Cohort	Overall	28.7 - 57.6 m	β-blockers	ACM
Springate et al, 2015	Cohort	Breast	3.2	β-blockers	ACM
Jansen et al, 2017	Cohort	Colorectal	79.2 m	β-blockers	ACM
Parker et al, 2017	Cohort	RCC	98.4 m	β-blockers	ACM
Musselma et al, 2018	Cohort	Breast	4.8	β-blockers	ACM
Kjellman et al, 2013	Cohort	Prostate	NR	α blockers	ACM
Murtola et al, 2013	Cohort	Prostate	NR	α blockers	ACM
Murtola et al, 2016	Cohort	Prostate	NR	α blockers	ACM
Kumar et al, 2019	Cohort	Prostate	NR	α blockers	ACM
Sarkar et al, 2019	Cohort	Prostate	NR	α blockers	ACM
Bardia et al, 2011	Cohort	Prostate	NR	ARBs	OS
Huang et al, 2011	Cohort	Breast	NR	ARBs	OS
Bhaskaran et al, 2012	Cohort	Breast	NR	ARBs	OS
Sendur et al, 2012	Cohort	Breast	NR	ARBs	OS
Chae et al, 2013	Cohort	Breast	NR	ARBs	OS
Sorensen et al, 2013	Cohort	Breast	NR	ARBs	OS
Wang et al, 2013	Cohort	Breast	NR	ARBs	OS
Cardwell et al, 2014	NCC	Colorectal	NR	ARBs	OS
Karagiannis et al, 2014	Cohort	Pancreatic	NR	ARBs	OS
Lam et al, 2014	Cohort	RCC	NR	ARBs	OS
Tuazon et al, 2014	Cohort	Colorectal	NR	ARBs	OS
Aydiner et al, 2015	CC	Lung	NR	ARBs	OS
FaCCiorusso et al, 2015	Cohort	HCC	NR	ARBs	OS
Osumi et al, 2015	Cohort	Colorectal	NR	ARBs	OS
Wang et al, 2015	Cohort	Lung	NR	ARBs	OS
Tascilar et al, 2016	Cohort	Breast	NR	ARBs	OS
Cerullo et al, 2017	Cohort	Pancreatic	NR	ARBs	OS
Chen et al, 2017	Cohort	Breast	NR	ARBs	OS
Fiala et al, 2021	Cohort	RCC	NR	ARBs	OS
Miura et al, 2021	Cohort	Lung	NR	ARBs	OS
Pereira et al, 2021	Cohort	Lung	NR	ARBs	OS
Fitzpatrick et al, 1997	Cohort	Breast	NR	ACEIs	OS
Chae et al, 2011	Cohort	Breast	8.2	ACEIs	OS

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Ganz et al, 2011	Cohort	Breast	8.2	ACEIs	OS
Chae et al, 2013	Cohort	Breast	NR	ACEIs	OS
Holmes et al, 2013	Cohort	Breast	NR	ACEIs	OS
Saltzman et al, 2013	Cohort	Breast	NR	ACEIs	OS
Sorensen et al, 2013	Cohort	Breast	NR	ACEIs	OS
Boudreau et al, 2014	Cohort	Breast	NR	ACEIs	OS
Cardwell et al, 2014	NCC	Colorectal	NR	ACEIs	OS
Karagiannis et al, 2014	Cohort	Pancreatic	NR	ACEIs	OS
Lam et al, 2014	Cohort	RCC	NR	ACEIs	OS
Tuazon et al, 2014	Cohort	Colorectal	NR	ACEIs	OS
FaCCiorusso et al, 2015	Cohort	HCC	NR	ACEIs	OS
Wang et al, 2015	Cohort	Lung	NR	ACEIs	OS
Wong et al, 2015	Cohort	Digestive and Respiratory	NR	ACEIs	OS
Chen et al, 2017	Cohort	Breast	NR	ACEIs	OS
Medjebar et al, 2020	Cohort	Lung	NR	ACEIs	OS
Buti et al, 2021	Cohort	Multiple	NR	ACEIs	OS
Fiala et al, 2021	Cohort	RCC	NR	ACEIs	OS
Pereira et al, 2021	Cohort	Lung	NR	ACEIs	OS
Hole et al, 1993	Cohort	Overall	NR	β blockers	OS
Powe et al, 2010	Cohort	Breast	120 m	β blockers	OS
Barron et al, 2011	CC	Breast	42 m	β-blockers	OS
De Giorgi et al, 2011	Cohort	Melanoma	30 m	β-blockers	OS
Ganz et al, 2011	Cohort	Breast	8.2 m	β-blockers	OS
Lemeshow et al, 2011	Cohort	Melanoma	4.9	β-blockers	OS
Melhem Bertrandt et al, 2011	Cohort	Breast	4.9	β-blockers	OS
Shah et al, 2011	Cohort	Mixed	NR	β-blockers	OS
Diaz et al, 2012	Cohort	Ovarian	NR	β-blockers	OS
Yusuf et al, 2012	Cohort	Mixed	NR	β-blockers	OS
Aydiner et al, 2013	CC	Lung	1.48	β-blockers	OS
Cardwell et al, 2013	NCC	Breast	72	β-blockers	OS
Chae et al, 2013	CC	Breast	NR	β-blockers	OS
DeGiorgi et al, 2013	Cohort	Melanoma	4.2	β-blockers	OS
Engineer et al, 2013	Cohort	Colorectal	NR	β-blockers	OS
Grytli et al, 2013	Cohort	Prostate	122 m	β-blockers	OS
Heitz et al, 2013	Cohort	Ovarian	1.42 m	β-blockers	OS
Hicks et al, 2013	NCC	Colorectal	6.2	β-blockers	OS
Holmes S et al, 2013	Cohort	Overall	4.2 -10.5	β-blockers	OS
Johannesdottir et al, 2013	Cohort	Ovarian	2.55	β-blockers	OS
Livingstone et al, 2013	Cohort	Melanoma	3.25	β-blockers	OS
Wang et al, 2013	Cohort	Lung	3.6	β-blockers	OS
Yang et al, 2017	Cohort	NSCLC	1.8	β-blockers	OS

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Assayag et al, 2014	Cohort	Prostate	3.8	β-blockers	OS
Cardwell et al, 2014	Cohort	Prostate	72 m	β-blockers	OS
Cata et al, 2014	Cohort	Lung	4.4	β-blockers	OS
Chae et al, 2014	Cohort	AML	1.1	β-blockers	OS
Grytli et al, 2014	Cohort	Prostate	3.2	β-blockers	OS
Jansen et al, 2014	Cohort	Colorectum	5	β-blockers	OS
Roque et al, 2014	Cohort	Endometrial	NR	β-blockers	OS
Bir et al, 2015	Cohort	brain tumors	10.5 m	β-blockers	OS
Brown et al, 2015	Cohort	Ovarian	NR	β-blockers	OS
Giampieri et al, 2015	Cohort	Colorectal	41.3 vs. 25.7 m	β-blockers	OS
Springate et al, 2015	Cohort	Overall	29, 30 m	β-blockers	OS
Watkins et al, 2015	Cohort	Ovarian	NR	β-blockers	OS
Al-Niaimi et al, 2016	Cohort	Ovarian	91 m	β-blockers	OS
Bar et al, 2016	Cohort	Ovarian	NR	β-blockers	OS
Cardwell et al, 2016	Cohort	Breast	72	β-blockers	OS
Failing et al, 2016	CC	Melanoma	NR	β-blockers	OS
Beg et al, 2017	Cohort	Pancreatic	NR	β-blockers	OS
Boas et al, 2017	Cohort	HCC	NR	β-blockers	OS
Heitz et al, 2017	Cohort	Ovarian	40 m	β-blockers	OS
Hwa et al, 2017	Cohort	Myeloma	74.3 m	β-blockers	OS
Jansen et al, 2017	Cohort	Colon-Rectum	6.6	β-blockers	OS
Kim et al, 2017	Cohort	Head and neck	99 m	β-blockers	OS
Udumyan et al, 2017	Cohort	Pancreatic	5 m	β-blockers	OS
Weberpals et al, 2017	Cohort	Overall	6.3	β-blockers	OS
Baek et al, 2018	Cohort	Ovarian	Users: 7, Nonusers: 6	β-blockers	OS
Musselma et al, 2018	Cohort	Overall	3.6	β-blockers	OS
Chang et al, 2019	Cohort	HCC	NR	β-blockers	OS
Cui et al, 2019	Cohort	Overall	4	β-blockers	OS
Fiala et al, 2019	Cohort	Colorectum	519 d	β-blockers	OS
Ahl et al, 2020	Cohort	Rectal	1	β-blockers	OS
Cortellini et al, 2020	Cohort	Multiple	24.2 m	β-blockers	OS
Hong et al, 2020	Cohort	Melanoma	NR	β-blockers	OS
Lee et al, 2020	Cohort	HCC	NR	β-blockers	OS
Michael et al, 2020	Cohort	NSCLC	NR	β-blockers	OS
Ohad et al, 2020	Cohort	Lung	16 m	β-blockers	OS
Regmi MR et al, 2020	Cohort	Breast	NR	β-blockers	OS
Udumyan et al, 2020	Cohort	Lung	1.6	β-blockers	OS
Wang et al, 2020	Cohort	Melanoma	NR	β-blockers	OS
Cortellini et al, 2021	Cohort	NSCLC	NR	β-blockers	OS
Kreklau et al, 2021	Cohort	Breast	NA	β-blockers	OS
Oh et al, 2021	Cohort	NSCLC	12.3 m	β-blockers	OS

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Posielski et al, 2021	Cohort	Prostate	134 m	β-blockers	OS
Silva et al, 2021	Cohort	RCC	NR	β-blockers	OS
Stoer et al, 2021	Cohort	Pancreatic	NR	β-blockers	OS
Yang et al, 2021	Cohort	Pancreatic	NR	β-blockers	OS
Mellgard et al, 2022	Cohort	Multiple	NR	β-blockers	OS
Wu et al, 2022	Cohort	HCC	NR	β-blockers	OS
Sorensen et al, 2000	Cohort	Colon	3.2	CCBs	OS
Lindberg et al, 2002	Cohort	Overall	NR	CCBs	OS
Koski et al, 2012	CC	Overall	NR	CCBs	OS
Holmes et al, 2013	Cohort	Colorectum	>1	CCBs	OS
Nakai et al, 2013	Cohort	Pancreatic	NR	CCBs	OS
Poch et al, 2013	Cohort	Prostate	NR	CCBs	OS
Chae et al, 2014	Cohort	AML	NR	CCBs	OS
He et al, 2015	Cohort	Esophageal	NR	CCBs	OS
Tingle et al, 2015	Cohort	Pancreatic	NR	CCBs	OS
Wong et al, 2015	Cohort	Overall	NR	CCBs	OS
Cui et al, 2019	Cohort	Overall	4	CCBs	OS
Fiala et al, 2019	Cohort	Colorectum	519 d	CCBs	OS
Takada et al, 2019	Cohort	Breast	NR	CCBs	OS
Tingle et al, 2020	Cohort	Pancreatic	NR	CCBs	OS
Stoer et al, 2021	Cohort	Pancreatic	NR	CCBs	OS
Holmes et al, 2013	Cohort	Colorectum	>1	Diuretics	OS
Mackenzie et al, 2016	Cohort	Pancreatic	NR	Diuretics	OS
Cui et al, 2019	Cohort	Overall	4	Diuretics	OS
Stoer et al, 2021	Cohort	Pancreatic	NR	Diuretics	OS
Heinzerling et al, 2007	Cohort	Colorectal	NR	ACEIs	DFS
Ganz et al, 2011	Cohort	Breast	NR	ACEIs	DFS
Boudreau et al, 2014	Cohort	Breast	NR	ACEIs	DFS
Chae et al, 2013	Cohort	Breast	NA	β-blockers	DFS
De Giorgi et al, 2011	Cohort	Melanoma	30 m	β-blockers	DFS
De Giorgi et al, 2013	Cohort	Melanoma	50.4 m	β-blockers	DFS
Diaz et al, 2012	Cohort	Ovarian	NR	β-blockers	DFS
Heitz et al, 2013	Cohort	Ovarian	17 m	β-blockers	DFS
Kim et al, 2017	Cohort	Head and Neck	98 m	β-blockers	DFS
Powe et al, 2010	Cohort	Breast	120 m	β-blockers	DFS
Roque et al, 2014	Cohort	Endometrial	NR	β-blockers	DFS
Sakellakis et al, 2014	Cohort	Breast	24/48 m	β-blockers	DFS
Wang et al, 2013	Cohort	Lung	44 m	β-blockers	DFS
Bardia et al, 2011	Cohort	Prostate	NR	ARBs	CSS
Wang et al, 2012	Cohort	Colorectal	NR	ARBs	CSS
Cardwell et al, 2014	NCC	Colorectal	NR	ARBs	CSS

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Osumi et al, 2015	Cohort	Colorectal	NR	ARBs	CSS
Tascilar et al, 2016	Cohort	Colorectal	NR	ARBs	CSS
Busby et al, 2018	Cohort	Gastro-oesophageal	NR	ARBs	CSS
Ganz et al, 2011	Cohort	Breast	NR	ACEIs	CSS
Ranasinghe et al, 2013	Cohort	Prostate	NR	ACEIs	CSS
Cardwell et al, 2014	NCC	Colorectal	NR	ACEIs	CSS
Powe et al, 2010	Cohort	Breast	10.3 m	β-blockers	CSS
Barron et al, 2011	Cohort	Breast	3.5, 3.6, 2.7, 3.0	β-blockers	CSS
Ganz et al, 2011	Cohort	Breast	8.2	β-blockers	CSS
Lemeshow et al, 2011	Cohort	Melanoma	4.9	β-blockers	CSS
Melhem-Bertrandt et al, 2011	Cohort	Breast	58.8 m	β-blockers	CSS
Botteri et al, 2013	Cohort	Breast	6, 5.6	β-blockers	CSS
Cardwell et al, 2013	NCC	Overall	6	β-blockers	CSS
Chae et al, 2013	CC	Breast	NR	β-blockers	CSS
DeGiorgi et al, 2013	Cohort	Melanoma	4.2	β-blockers	CSS
Grytli et al, 2013	Cohort	Prostate	121 m	β-blockers	CSS
Hicks et al, 2013	NCC	Colorectal	6.2	β-blockers	CSS
Holmes et al, 2013	Cohort	Breast	10.5	β-blockers	CSS
Assayag et al, 2014	Cohort	Prostate	3.8	β-blockers	CSS
Cardwell et al, 2014	NCC	Prostate	6	β-blockers	CSS
Grytli et al, 2014	Cohort	Prostate	3.25	β-blockers	CSS
Jansen et al, 2014	Cohort	Colorectal	5	β-blockers	CSS
MCCourt et al, 2014	NCC	Melanoma	7.5	β-blockers	CSS
Brown et al, 2015	Cohort	Ovarian	5.8	β-blockers	CSS
Watkins et al, 2015	Cohort	Ovarian	NR	β-blockers	CSS
Hwa et al, 2017	Cohort	Myeloma	74.3 m	β-blockers	CSS
Kim et al, 2017	Cohort	Head and neck	98 m	β-blockers	CSS
Parker et al, 2017	Cohort	RCC	98.4 m	β-blockers	CSS
Udumyan et al, 2017	Cohort	Pancreatic	5 m	β-blockers	CSS
Cui et al, 2019	Cohort	Breast	NR	β-blockers	CSS
Santala et al, 2020	Cohort	Breast	NR	β-blockers	CSS
Løfling et al, 2021	Cohort	Breast	NR	β-blockers	CSS
Osumi et al, 2015	Cohort	Colorectal	NR	ARBs	PFS
Fiala et al, 2021	Cohort	RCC	NR	ARBs	PFS
Pereira et al, 2021	Cohort	Lung	NR	ARBs	PFS
Medjebar et al, 2020	Cohort	Lung	NR	ACEIs	PFS
Fiala et al, 2021	Cohort	RCC	NR	ACEIs	PFS
Pereira et al, 2021	Cohort	Lung	NR	ACEIs	PFS
Diaz et al, 2012	Cohort	Ovarian	NR	β-blockers	PFS
Heitz et al, 2013	Cohort	Ovarian	17 m	β-blockers	PFS
Wang et al, 2013	Cohort	Lung	44 m	β-blockers	PFS

First Author	Design	Type of Cancer	Follow-up Time (y)	Intervention	Outcome
Jansen et al, 2014	Cohort	Colorectum	5	β-blockers	PFS
Giampieri et al, 2015	Cohort	Colorectum	8.3 vs. 7.1 m	β-blockers	PFS
Failing et al, 2016	CC	Melanoma	NR	β-blockers	PFS
Heitz et al, 2017	Cohort	Ovarian	40 m	β-blockers	PFS
Sud et al, 2018	Cohort	Colorectum	NR	β-blockers	PFS
Bowles et al, 2019	Cohort	Colon	4.9	β-blockers	PFS
Fiala et al, 2019	Cohort	Colorectum	519 d	β-blockers	PFS
Cortellini et al, 2020	Cohort	Multiple	24.2 m	β-blockers	PFS
Michael et al, 2020	Cohort	NSCLC	NR	β-blockers	PFS
Wang et al, 2020	Cohort	Melanoma	NR	β-blockers	PFS
Cortellini et al, 2021	Cohort	NSCLC	NR	β-blockers	PFS
Kreklau et al, 2021	Cohort	Breast	NA	β-blockers	PFS
Oh et al, 2021	Overall	NSCLC	12.3 m	β-blockers	PFS
Silva et al, 2021	Cohort	RCC	NR	β-blockers	PFS
Bowles et al, 2019	Cohort	Colon	4.9	CCBs	PFS
Fiala et al, 2019	Cohort	Colorectum	519 d	CCBs	PFS
Botteri E et al, 2013	Cohort	Breast	72 m (β blocker), 68 m (control)	β-blockers	RFS
Cata et al, 2014	Cohort	Lung	NR	β-blockers	RFS
Chen et al, 2017	Cohort	Breast	3	β-blockers	RFS
Choy et al, 2016	Cohort	Breast	NR	β-blockers	RFS
Jansen et al, 2014	Cohort	Colorectal	60 m	β-blockers	RFS
Lorona et al, 2021	Cohort	Breast	NR	β-blockers	RFS
Sørensen et al, 2013	Cohort	Breast	NR	β-blockers	RFS

CC, case-control; NCC, nested case-control; m, month; NR, not reported; NA, not assessable; ARBs, angiotensin receptor blockers; ACEIs, angiotensin converting enzyme inhibitors; CCBs, calcium channel blockers; PDE5Is, phosphodiesterase 5 inhibitors; CSM, cancer-specific mortality; ACM, all-cause mortality; OS, overall survival; DFS, disease-free survival; CSS, cancer-specific survival; PFS, progression-free survival; RFS, recurrence-free survival; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; AML, acute myeloid leukemia; MCC, merkel cell carcinoma; NMSC, non-melanoma skin cancer; NSCLC, non-small cell lung cancer

Supplemental Table 12. Summary characteristics of included original research articles across meta-analyses of randomized controlled trials

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
IDNT	2001	Overall	31 m	HTN, DM + nephropathy	ARBs	Placebo	Incidence	L
IRMA 2	2001	Overall	2	HTN with T2DM and microalbuminuria	ARBs	Placebo	Incidence	H
RENAAL	2001	Overall	3.4	HTN with CKD	ARBs	Placebo	Incidence	L
Val-HeFT	2001	Overall	23 m	Symptomatic CHF	ARBs	Placebo	Incidence	L
LIFE	2002	Overall	4.9	HTN	ARBs	β-blockers	Incidence	L
ALPINE	2003	Overall	1	HTN	ARBs	HCTZ	Incidence	H
CHARM-Overall	2003	Overall	37.7 m	High risk CHF	ARBs	Placebo	Incidence	L
PROFESS	2003	Overall	2.5	Recent (median 15 d) ischemic stroke	ARBs	Placebo	Incidence	L
VALIANT	2003	Overall	24.7 m	Recent (up to 10 d) AMI	ARBs	Captopril	Incidence	L
VALUE	2004	Overall	4.2	HTN with high-risk cardiac events	ARB-based	CCB-based	Incidence	L
MOSES	2005	Overall	3.3	NR	ARBs	CCBs	Incidence	L
SCOPE	2006	Overall	44.4 m	Elderly with mild-to-moderate HTN	ARBs	Placebo	Incidence	L
JIKEI	2007	Overall	3.1	HTN	ARBs	Conventional therapy	Incidence	H
CASE−J	2008	Overall	3.1	NR	ARBs	CCBs	Incidence	L
DIRECT (all)	2008	Overall	56.4 m	T1DM without retinopathy	ARBs	Placebo	Incidence	L
I-PRESERVE	2008	Overall	4.1	CHF with preserved LVEF	ARBs	Placebo	Incidence	L
ONTARGET	2008	Overall	4.8	CVD or DM with end-organ damage	ARBs	ACEIs, ACEIs/ARBs	Incidence	L
TRANSCEND	2008	Overall	4.9	CVD or DM with end-organ damage	ARBs	Placebo	Incidence	L
TROPHY	2008	Overall	48.5 m	Pre HTN	ARBs	Placebo	Incidence	L
GISSI-AF	2009	Overall	1	AF	ARBs	Placebo	Incidence	L
HIJ−CREATE	2009	Overall	4.2	HTN with CAD	ARBs	Non-ARBs	Incidence	L
KYOTO	2009	Overall	3.3	HTN	ARBs	Conventional therapy	Incidence	L
NAVIGATOR	2010	Overall	60 m	IGT with established CVD or CV risk factors	ARBs	Placebo	Incidence	L
ACTIVE I	2011	Overall	4.1	AF plus 1 risk factor for stroke	ARBs	Placebo	Incidence	L
ANTIPAF	2011	Overall	1	AF	ARBs	Placebo	Incidence	H
COPE	2011	Overall	3.6	NR	ARBs (/CCB)	CCBs/β-blockers, CCBs/Thiazides	Incidence	H
HOMED−BP	2012	Overall	4.9	NR	ARBs	ACEIs, CCBs	Incidence	H
OCTOPUS	2013	Overall	3.5	HTN with ESRD	ARBs	Non-ARBs	Incidence	H

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
PREVER-treatment	2016	Overall	1.5	HTN	ARBs	Chlorthalidone/ Amiloride	Incidence	L
SOLVD-T	1991	Overall	3.5	HF	ACEIs	Placebo	Incidence	L
SOLVD-P	1992	Overall	3.1	HF with LVEF ≤ 35%	ACEIs	Placebo	Incidence	L
AIPRI	1996	Overall	3	CKD	ACEIs	Placebo	Incidence	H
GISEN	1997	Overall	1.3	CKD (nondiabetic nephropathy)	ACEIs	Placebo	Incidence	H
ABCD	1998	Overall	4.7	Normotension and HTN with T2DM	ACEIs	CCBs	Incidence	L
FACET	1998	Overall	2.9	HTN with T2DM	ACEIs	CCBs	Incidence	L
STOP−2	1999	Overall	4.5	HTN	ACEIs	β-blockers and/or Thiazides, CCBs	Incidence	L
APRES	2000	Overall	2.7	CAD (after PCI)	ACEIs	Placebo	Incidence	H
HOPE	2000	Overall	4.5	Patients high risk of cardiovascular events	ACEIs	Placebo	Incidence	L
PART−2	2000	Overall	4.6	NR	ACEIs	Placebo	Incidence	L
SCAT	2000	Overall	4	CAD	ACEIs	Placebo	Incidence	L
ESPIRAL	2001	Overall	3	HTN with CKD	ACEIs	Non-ACEIs	Incidence	H
Val-HeFT	2001	Overall	1.9	HF	ACEIs	Non-ACEIs	Incidence	L
AASK	2002	Overall	4.8	NR	ACEIs	β-blockers, CCBs	Incidence	L
ALLHAT	2002	Overall	4.8	HTN with at least 1 risk factor for CHD event	ACEIs	CCBs, Thiazides, α blockers	Incidence	L
ANBP2	2003	NR	4.1	NR	ACEIs	Thiazides	Incidence	H
CHARM Added	2003	Overall	3.4	HF	ACEIs	Placebo	Incidence	L
EUROPA	2003	NR	4.2	NR	ACEIs	Placebo	Incidence	L
VALIANT	2003	Overall	2.1	HF or LVSD post MI	ACEIs	Non-ACEIs	Incidence	L
BENEDICT	2004	Overall	3.1	NR	ACEIs	ACEIs/CCBs, CCBs, Placebo	Incidence	L
CAMELOT	2004	Overall	1.6	Normotension with CAD	ACEIs	CCBs, Placebo	Incidence	L
DIABHYCAR	2004	NR	3.9	NR	ACEIs	Placebo	Incidence	L
JMIC−B	2004	NR	2.3	NR	ACEIs	CCBs	Incidence	L
NESTOR	2004	Overall	1	HTN with T2DM	ACEIs	Non-ACEIs	Incidence	H
PHYLLIS	2004	Overall	2.6	Carotid Atherosclerosis	ACEIs	HCTZ + Pravastatin	Incidence	H
PREVEND IT	2004	NR	3.8	NR	ACEIs	Placebo	Incidence	L
TRACE	2005	Overall	5.6	HF with LVEF ≤ 35%	ACEIs	Placebo	Incidence	L
ONTARGET	2008	Overall	4.8	CVD or DM with end-organ damage	ACEIs	ACEIs/ARBs, ARBs	Incidence	L

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
PHARAO	2008	Overall	3	Pre-HTN	ACEIs	Placebo	Incidence	L
DEMAND	2011	Overall	3.8	HTN with T2DM and albuminuria	ACEIs	Non-ACEIs	Incidence	L
HOMED−BP	2012	NR	4.9	NR	ACEIs	ARBs, CCBs	Incidence	H
PARADIGM-HF	2014	Overall	2.2	HF with EF ≤ 40%	ACEIs	Non-ACEIs	Incidence	L
HEP	1896	Overall	4.4	HTN	β-blockers	Non-BBs	Incidence	H
BHAT	1982	Overall	2.1	Post-MI	β-blockers	Placebo	Incidence	L
VA COOP II	1982	Overall	1	HTN	β-blockers	HCTZ	Incidence	L
Coope & Warrender	1986	Overall	4.4	HTN	β-blockers	Quinapril	Incidence	H
STOP2 (Overall)	1999	Overall	5	HTN	β-blockers	Conventional therapy	Incidence	L
MERIT-HF	2001	Overall	1	HF	β-blockers	Placebo	Incidence	L
AASK	2002	Overall	4.8	NR	β-blockers	ACEIs, CCBs	Incidence	L
ELSA	2002	Overall	3.4	NR	β-blockers	CCBs	Incidence	L
LIFE	2002	Overall	4.9	HTN	β-blockers	ARBs	Incidence	L
CONVINCE	2003	Overall	3	HTN	β-blockers	Non-BBs	Incidence	L
INVEST	2003	Overall	2.7	HTN	β-blockers	Non-BBs	Incidence	L
ASCOT−BPLA	2005	Overall	5.3	HTN with at least 3 other CVD risk	b-blocker-based	CCB-based	Incidence	L
COPE	2011	Overall	3.6	NR	b-blocker (/CCB)	CCBs/ARBs, CCBs/Thiazides	Incidence	H
VERDI	1989	Overall	1	HTN	CCBs	HCTZ	Incidence	L
MIDAS	1996	Overall	3	HTN	CCBs	HCTZ	Incidence	H
PRAISE	1996	Overall	1.2	HF	CCBs	Placebo	Incidence	H
STONE	1996	Overall	2.5	HTN	CCBs	Placebo	Incidence	H
Syst−Eur	1997	Overall	2.6	HTN	CCBs	Placebo	Incidence	L
ABCD	1998	Overall	4.7	Normotension and HTN with T2DM	CCBs	ACEIs	Incidence	L
FACET	1998	Overall	2.9	HTN with T2DM	CCBs	Non-CCBs	Incidence	L
DAVIT II	1999	Overall	1.3	CAD (after MI)	CCBs	Placebo	Incidence	L
Kanamasa et al, 1999	1999	Overall	2.2	CAD (AMI)	CCBs	Placebo	Incidence	H
NICS−EH	1999	Overall	3.2	Elderly HTN	CCBs	Thiazides	Incidence	L
STOP−2	1999	Overall	4.5	HTN	CCBs	ACEIs, β-blockers and/or Thiazides	Incidence	L
INSIGHT	2000	Overall	4.5	HTN	CCBs	Non-CCBs	Incidence	L

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
PREVENT	2000	Overall	3	CHD	CCBs	Placebo	Incidence	L
ESPIRAL	2001	Overall	3	HTN with CKD	CCBs	Non-CCBs	Incidence	H
AASK	2002	Overall	4.8	NR	CCBs	ACEIs, β-blockers	Incidence	L
ALLHAT	2002	Overall	4.8	HTN with at least 1 risk factor for CHD event	CCBs	ACEIs, Thiazides, α blockers	Incidence	L
ELSA	2002	Overall	3.4	NR	CCBs	β-blockers	Incidence	L
CONVINCE	2003	Overall	2.8	HTN	CCBs	β-blockers/ Thiazides	Incidence	L
IDNT (Overall)	2003	Overall	2.6	HTN with T2DM nephropathy	CCBs	Non-CCBs	Incidence	L
INVEST	2003	Overall	2.8	HTN with CHD	CCBs	Non-CCBs	Incidence	L
NICOLE	2003	Overall	3	CAD (after PCI)	CCBs	Placebo	Incidence	H
ACTION	2004	Overall	4.9	HTN with CAD	CCBs	Placebo	Incidence	L
BENEDICT	2004	Overall	3.1	NR	CCBs	ACEIs, ACEIs/CCBs, Placebo	Incidence	L
CAMELOT	2004	Overall	1.6	Normotension with CAD	CCBs	ACEIs, Placebo	Incidence	L
JMIC−B	2004	Overall	2.3	NR	CCBs	ACEIs	Incidence	L
VALUE	2004	Overall	4.2	HTN with high-risk cardiac events	CCB-based	ARB-based	Incidence	L
ASCOT−BPLA	2005	Overall	5.3	HTN with at least 3 other CVD risk	CCB-based	β blocker-based	Incidence	L
FEVER	2005	Overall	3.3	HTN	CCBs	Placebo	Incidence	L
MOSES	2005	Overall	3.3	NR	CCBs	ARBs	Incidence	L
CASE−J	2008	Overall	3.1	High risk HTN	CCBs	ARBs	Incidence	L
HOMED−BP	2012	Overall	4.9	NR	CCBs	ACEIs, ARBs	Incidence	H
NHS	2012	Overall	3.2	HTN with T2DM or IGT	CCBs	Non-CCBs	Incidence	H
COLM	2014	Overall	3	NR	CCB (/ARB)	ARBs/Thiazides	Incidence	L
HSCSG	1974	Overall	3	CVA	Diuretics	Placebo	Incidence	H
VA COOP II	1982	Overall	1	HTN	Diuretics	Non-TZs	Incidence	L
EWPHE	1985	Overall	4.6	Elderly with HTN	Diuretics	Placebo	Incidence	L
VERDI	1989	Overall	1	HTN	Diuretics	Verapamil	Incidence	L
MIDAS	1996	Overall	3	HTN	Diuretics	Non-TZs	Incidence	H
NICS−EH	1999	Overall	3.2	Elderly HTN	Diuretics	CCBs	Incidence	L
INSIGHT	2000	Overall	4.5	HTN	Diuretics	Non-TZs	Incidence	L
LaCroix	2000	Overall	3	Healthy adult	Diuretics	Placebo	Incidence	L

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
ALLHAT	2002	Overall	4.8	HTN with at least 1 risk factor for CHD event	Diuretics	ACEIs, CCBs, α blockers	Incidence	L
ALPINE	2003	Overall	1	HTN	Diuretics	Non-TZs	Incidence	H
ANBP2	2003	Overall	4.1	NR	Diuretics	ACEIs	Incidence	H
NESTOR	2004	Overall	1	HTN with T2DM	Diuretics	Enalapril	Incidence	H
PHYLLIS	2004	Overall	2.6	HTN with hypercholesterol aemia	Diuretics	Non-TZs	Incidence	H
COPE	2011	Overall	3.6	NR	Diuretics (/CCB)	CCBs/ARBs and CCBs/ß-blockers	Incidence	H
COLM	2014	Overall	3	NR	Diuretics (/ARB)	ARBs/CCBs	Incidence	L
PREVER-treatment	2016	Overall	1.5	HTN	Diuretics	Non-TZs	Incidence	L
Bakris et al, 2015	2015	Overall	3 m	T2DM with CKD	Finerenone	Placebo	Incidence	L
Filippatos et al, 2016	2016	Overall	3 m	T2DM with CKD	Finerenone	Placebo	Incidence	L
Bakris et al, 2020	2020	Overall	31.2 m	T2DM with CKD	Finerenone	Placebo	Incidence	L
Pitt et al, 2021	2021	Overall	40.8 m	T2DM with CKD	Finerenone	Placebo	Incidence	L
IRMA 2	2001	Overall	2	HTN with T2DM and microalbuminuria	ARBs	Placebo	CSM	H
RENAAL	2001	Overall	3.4	HTN with CKD	ARBs	Placebo	CSM	L
VALHEFT	2001	Overall	1.9	HF	ARBs	Placebo	CSM	L
Life	2002	Overall	4.8	HTN	ARBs	Atenolol	CSM	L
OPTIMAAL	2002	Overall	2.7	HF and CAD (AMI)	ARBs	Captopril	CSM	L
CHARM-Overall	2003	Overall	3.1	HF	ARBs	Placebo	CSM	L
IDNT (Overall)	2003	Overall	2.6	HTN with type 2 diabetic nephropathy	ARBs	Non-ARBs	CSM	L
VALIANT	2003	Overall	2.1	HF with CAD (after MI)	ARBs	Captopril	CSM	L
VALUE	2004	Breast	4.2	High-risk hypertensive patients	ARBs	Amlodipine	CSM	L
E-COST	2005	Overall	3.1	HTN	ARBs	Conventional therapy	CSM	H
SCOPE	2006	Breast	3.7	Elderly with mild-to-moderate HTN	ARBs	Placebo	CSM	L
DIRECT (all)	2008	Breast	56.4 m	T1DM without retinopathy	ARBs	Placebo	CSM	L
ONTARGET	2008	Overall	4.7	Cardiovascular disease or diabetes with end-organ damage	ARBs	Ramipril	CSM	L
Profess	2008	Overall	2.5	Recent (<90 d) ischaemic stroke	ARBs	Placebo	CSM	L
Suzuki	2008	Overall	3	CKD (ESRD on dialysis)	ARBs	Non-ARBs	CSM	H
Transcend	2008	Overall	4.7	CVD or DM with end-organ damage	ARBs	Placebo	CSM	L
TROPHY	2008	Breast	3.6	Pre-HTN	ARBs	Placebo	CSM	L

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
GISSI-AF	2009	Overall	1	AF	ARBs	Placebo	CSM	L
HIJ-CREATE	2009	Overall	4.2	HTN with CAD	ARBs	Non-ARBs	CSM	H
KYOTO	2009	Overall	3.3	HTN	ARBs	Conventional therapy	CSM	L
I-Preserve	2010	Overall	4.1	HF	ARBs	Placebo	CSM	L
NAVIGATOR	2010	Breast	60 m	IGT with established CVD or CV risk factors	ARBs	Placebo	CSM	L
ACTIVE I	2011	Breast	49 m	AF plus one risk factor for stroke	ARBs	Placebo	CSM	L
ANTIPAF	2011	Overall	1	AF	ARBs	Placebo	CSM	L
NHS	2012	Overall	3.2	HTN with T2DM or IGT	ARBs	Amlodipine	CSM	H
OCTOPUS	2013	Overall	3.5	HTN with ESRD	ARBs	Non-ARBs	CSM	H
V-heft II	1991	Overall	2.5	HF	ACEIs	Non-ACEIs	CSM	L
MMHF	1992	Overall	2.7	Systolic HF	ACEIs	Placebo	CSM	H
SAVE	1992	Overall	3.5	HF with CAD (after MI)	ACEIs	Placebo	CSM	L
GLANT	1995	Overall	1	HTN	ACEIs	CCBs	CSM	H
FACET	1998	Overall	2.9	HTN with T2DM	ACEIs	Amlodipine	CSM	L
UKPDS	1998	Overall	9	HTN with T2DM	ACEIs	Atenolol	CSM	L
APRES	2000	Overall	2.7	CAD (after PCI)	ACEIs	Placebo	CSM	H
VALHEFT	2001	Overall	1.9	HF	ACEIs	Placebo	CSM	L
ALLHAT (Overall)	2002	Overall	4.9	HTN with vascular disease risk factors	ACEIs	Chlorthalidone + Amlodipine	CSM	L
OPTIMAAL	2002	Overall	2.7	HF and CAD (AMI)	ACEIs	Losartan	CSM	L
CHARM Added	2003	Overall	3.4	HF	ACEIs	Placebo	CSM	L
VALIANT	2003	Overall	2.1	HF with CAD (after MI)	ACEIs	Non-ACEIs	CSM	L
DIABHYCAR	2004	Overall	4	T2DM with albuminuria	ACEIs	Placebo	CSM	L
Otsuka et al, 2004	2004	Overall	4.8	CAD (after PCI)	ACEIs	Non-ACEIs	CSM	H
QUINS	2007	Overall	3	Scleroderma	ACEIs	Placebo	CSM	H
ONTARGET	2008	Overall	4.7	CVD or DM with end-organ damage	ACEIs	ARBs	CSM	L
PHARAO	2008	Overall	3	Pre-HTN	ACEIs	Placebo	CSM	L
DEMAND	2011	Overall	3.8	HTN with T2DM and albuminuria	ACEIs	Non-ACEIs	CSM	L
PARADIGM-HF	2014	Overall	2.2	HF with EF ≤ 40%	ACEIs	Non-ACEIs	CSM	L
HEP	1896	Overall	4.4	HTN	β-blockers	Non-BBs	CSM	H

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
Practolol Trial	1975	Overall	1.2	Post-MI	β-blockers	Placebo	CSM	H
Wilcox et al, 1980	1980	Overall	1	Suspected MI	β-blockers	Placebo	CSM	H
MRC (Overall)	1985	Overall	4.9	HTN	β-blockers	Placebo	CSM	H
SMT	1985	Overall	3	Post-MI	β-blockers	Placebo	CSM	H
MAPHY	1988	Overall	4.2	HTN	β-blockers	Non-BBs	CSM	H
MRCOA (Overall)	1992	Overall	5.8	HTN	β-blockers	Placebo	CSM	H
UKPDS	1998	Overall	9	HTN with T2DM	β-blockers	Conventional therapy	CSM	L
LIFE	2002	Overall	4.8	HTN	β-blockers	Non-BBs	CSM	L
PAT	2002	Overall	2.5	Asymptomatic small AAA	β-blockers	Placebo	CSM	L
CONVINCE	2003	Overall	3	HTN	β-blockers	Non-BBs	CSM	L
ASCOT-BPLA	2005	Overall	5.5	HTN with at least 3 other CVD risk	β-blockers	Non-BBs	CSM	L
APSIS	2006	Overall	9.1	CAD	β-blockers	Verapamil	CSM	H
INTACT	1990	Overall	3	Mild CHD	CCBs	Placebo	CSM	H
GLANT	1995	Overall	1	HTN	CCBs	Delapril	CSM	H
MIDAS	1996	Overall	3	HTN	CCBs	HCTZ	CSM	H
Syst-Eur	1997	Overall	2	HTN	CCBs	Placebo	CSM	L
FACET	1998	Overall	2.9	HTN with T2DM	CCBs	Non-CCBs	CSM	L
SPRINT	1998	Overall	5	CHD post-MI	CCBs	Placebo	CSM	H
Kanamasa et al, 1999	1999	Overall	2.2	CAD (after MI)	CCBs	Placebo	CSM	H
NICS EH	1999	Overall	4.6	HTN	CCBs	Trichlormethiazide	CSM	H
Syst-China	2000	Overall	4	HTN	CCBs	Placebo	CSM	L
ALLHAT (Overall)	2002	Overall	4.9	HTN with vascular disease risk factors	CCBs	Chlortalidone	CSM	L
CONVINCE	2003	Overall	3	HTN	CCBs	Atenolol	CSM	L
IDNT (Overall)	2003	Overall	2.6	HTN with type 2 diabetic nephropathy	CCBs	Placebo	CSM	L
ASCOT-BPLA	2005	Overall	5.5	HTN	CCBs	Atenolol based regimen	CSM	L
REIN 2	2005	Overall	1.6	CKD (nondiabetic)	CCBs	Conventional AHT	CSM	L
APSIS	2006	Overall	9.1	CAD	CCBs	Metoprolol	CSM	H
NHS	2012	Overall	3.2	HTN with T2DM or IGT	CCBs	Non-CCBs	CSM	H
ANBP	1980	Overall	4	Mild HTN	Diuretics	Placebo	CSM	H

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
OSLO	1980	Overall	5.5	HTN	Diuretics	No treatment	CSM	H
MRC (Overall)	1985	Overall	4.9	HTN	Diuretics	Propranolol, Placebo	CSM	H
MAPHY	1988	Overall	4.2	HTN	Diuretics	Metoprolol	CSM	H
SHEP	1991	Overall	4.5	HTN	Diuretics	Placebo	CSM	H
MRCOA (Overall)	1992	Overall	5.8	HTN	Diuretics	Atenolol, Placebo	CSM	H
MIDAS	1996	Overall	3	HTN	Diuretics	Non-TZs	CSM	H
NICS EH	1999	Overall	4.6	HTN	Diuretics	Non-TZs	CSM	H
ALLHAT (Overall)	2002	Overall	4.9	HTN with vascular disease risk factors	Diuretics	Non-TZs	CSM	L
PREVER-treatment	2016	Overall	1.5	HTN	Diuretics	Non-TZs	CSM	L
LIFE	2002	Overall	4.8	HTN	ARBs	Atenolol	ACM	L
CHARM-Overall	2003	Overall	3.1	HF	ARBs	Placebo	ACM	L
TRANSCEND	2008	Overall	4.7	ACE-inhibitor intolerant patients with CVD or DM, with end-organ damage	ARBs	Placebo	ACM	L
ONTARGET	2008	Overall	4.7	CVD or DM with end-organ damage	ARBs	Ramipril	ACM	L
PROFESS	2008	Overall	2.5	Recent (<90 d) ischemic stroke	ARBs	Placebo	ACM	L
Nihat Kalay et al, 2006	2006	Overall	NR	NR	β-blockers	Placebo	ACM	H
Georgakopoulos et al, 2010	2010	Lymphoma	NR	NR	β-blockers	NR	ACM	H
Salehi et al, 2011	2011	Overall	4 m	NR	β-blockers	Placebo	ACM	H
Bosch et al, 2013	2013	Overall	6 m	Acute leukemia or patients with malignant hematopathies	β-blockers	Placebo	ACM	H
Kaya et al, 2013	2013	Breast	NR	NR	β-blockers	NR	ACM	H
Jhorawat et al, 2014	2014	Overall	NR	NR	β-blockers	Placebo	ACM	H
Elitok et al, 2014	2014	Breast	NR	NR	β-blockers	NR	ACM	H
Nabati et al, 2017	2017	Breast	6 m	NR	β-blockers	Placebo	ACM	H
Avila et al, 2018	2018	Breast	6 m	Patients with HER2-negative breast cancer tumor status	β-blockers	Placebo	ACM	H
Cochera et al, 2018	2018	Breast	NR	NR	β-blockers	NR	ACM	H
Abousa et al, 2018	2018	Breast	6 m	NR	β-blockers	Placebo	ACM	H
Heck et al, 2021	2021	Breast	NR	NR	β-blockers	NR	ACM	H
Spera G et al, 2017	2017	Breast	NR	NR	β-blockers	NR	OS	H
Modiet et al, 2020	2020	Breast	NR	NR	β-blockers	Nonusers	OS	H

First Author or Trial Name	Year	Type of Cancer	Follow-up Time (y)	Population	Intervention	Comparison	Outcome	RoB
Kichenadasse et al, 2021	2021	Overall	NR	NR	β-blockers	NR	OS	H
Millward et al, 1993	1993	Lung	NR	NR	CCBs	NR	OS	H
Mross et al, 1993	1993	Breast	NR	NR	CCBs	NR	OS	H
Belpomme et al, 2000	2000	Breast	NR	NR	CCBs	NR	OS	H
Spera et al, 2017	2017	Breast	NR	NR	β-blockers	Nonusers	PFS	H
Modi et al, 2020	2020	Breast	NA	NR	β-blockers	Non-BBs	PFS	H
Kichenadasse et al, 2021	2021	Overall	NR	NR	β-blockers	NR	PFS	H
Kennedy et al, 2022	2022	Melanoma	37 m	NR	β-blockers	NR	PFS	H

RoB, risk of bias; L, low; H, high; m, month; NR, not reported; NA, not assessable; ARBs, angiotensin receptor blockers; ACEIs, angiotensin converting enzyme inhibitors; CCBs, calcium channel blockers; CSM, cancer-specific mortality; ACM, all-cause mortality; OS, overall survival; PFS, progression-free survival; HCTZ, hydrochlorothiazide; BBs, β blockers; TZs, thiazides; AHT, antihypertensive treatment; DM, diabetes mellitus; T2DM, type 2 diabetes mellitus; CKD, chronic kidney disease; CHF, congestive heart failure; AMI, acute myocardial infarction; T1DM, type 1 diabetes mellitus; LVEF, left ventricular ejection fraction; CVD, cardiovascular disease; AF, atrial fibrillation; CAD, coronary artery disease; CV, cardiovascular; ESRD, end-stage renal disease; PCI, percutaneous coronary intervention; CHD, coronary heart disease; HF, heart failure; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; EF, ejection fraction; IGT, impaired glucose tolerance; CVA, cerebrovascular accident; AAA, abdominal aortic aneurysm